[1] Barritt AS 4th, Barnhart H, Gu J, Dellinger A, et al. When is suspected drug-induced liver injury (DILI) not DILI? ananalysis of unlikely cases from the drug-induced liver injury network. Am J Gastroenterol, 2023, 118(12):2301-2304. [2] 李容容,李盟,罗琼,等.国内外药物性肝损伤临床诊疗指南的比较分析.中华肝脏病杂志,2023,31(4):433-439. [3] Akemi T, Kenichi H, Koichi T, et al. Histopathological analysis of autoimmune hepatitis with "acute presentation:Differentiation from drug induced liver injury. Hepatol Res, 2020, 50(9): 1047-1061. [4] Yang Z, Wu W, Ou P, et al. MiR-122-5p knockdown protects against APAP-mediated liver injury through up-regulating NDRG3. Mol Cell Biochem, 2021, 476(2):1257-1267. [5] Sullivan KM, Jiang X, Guha P, et al. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. Gut, 2023, 72(2):325-337. [6] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南.中华肝脏病杂志,2015,23(11):810-820. [7] Devarbhavi H, Kurien SS, Raj S, et al. Idiosyncratic drug-induced liver injury associatedwith and without drug reaction with eosinophilia and systemic symptoms. Am J Gastroenterol, 2022, 117(10):1709-1713. [8] Lauschke VM. Toxicogenomics of drug induced liver injury - from mechanistic understanding to early prediction. Drug Metab Rev, 2021, 53(2):245-252. [9] Ishida T, Kawada K, Jobu K, et al. Analysis of drug-induced liver injury from bofutsushosan administration usingJapanese adverse drug event report (JADER) database. Biol Pharm Bull, 2022, 45(4):460-466. [10] 赵瑞红,马科,胡静,等.大型综合性医院感染科住院肝病患者病因近20年流行病学现状.中华肝脏病杂志,2018,26(2):136-141. [11] Marquez L, Raheja R, Chan-Liston M, et al. Industry review of best practices for risk management of drug-induced liver injury fromdevelopment to real-world use. Drug Saf, 2024, 47(1):1-22. [12] Walker PA, Ryder S, Lavado A, et al. The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development. Arch Toxicol, 2020, 94(8):2559-2585. [13] Sunago K, Abe M, Yoshida O, et al. Clinical and pathological features of immune checkpoint inhibitor-induced liver injury in comparison with drug-induced liver injury and autoimmune hepatitis. J Gastrointestin Liver Dis, 2023, 32(4):488-496. [14] Cohen EB, Patwardhan M, Raheja R, et al. Drug-induced liver injury in the elderly: consensus statements and recommendations from the IQ-DILI initiative. Drug Saf, 2024, 47(4):301-319. [15] Huang YS, Chang TT, Peng CY, et al. Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury. Hepatol Int, 2021, 15(6):1456-1465. [16] Parayath NN, Gandham SK, Amiji MM. Tumor-targeted miRNA nanomedicine for overcoming challenges in immunity and therapeutic resistance. Nanomedicine(Lond), 2022, 17(19):1355-1373. [17] 刘永莲,朱凯,孙宝飞,等.MiR-155在砷致肝损伤大鼠Th17/Treg稳态失衡中的作用及机制研究.中华地方病学杂志,2024,43(4):276-284. [18] Klieser E, Mayr C, Kiesslich T, et al. The crosstalk of miRNA and oxidative stress in the liver: from physiology to pathology and clinical implications. Int J Mol Sci, 2019, 20(21) : 5266. [19] 邱春芳,吴健锋,裴飞,等.双链RNA依赖的蛋白激酶活性抑制剂对脓毒症小鼠器官损伤及炎症因子的影响.中华医学杂志,2020,100(13):1033-1037. [20] 窦晓伟,张卉,张克明,等.白细胞介素-35在小鼠脓毒症肝损伤早期的保护作用.中华实验外科杂志,2021,38(10):1901-1905. [21] Zhang K, Xu X, Hu L. Sevoflurane attenuates hepatic ischemia reperfusion injury by the miR-122/Nrf2 pathway. Ann Transl Med, 2022, 10(6):350. |